Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action

[Image: see text] The free fatty acid receptors FFAR1 and FFAR4 are considered promising therapeutic targets for management of metabolic and inflammatory diseases. However, there is a need for entirely novel chemical scaffolds, since many of the highly similar lipophilic chemotypes in development ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lückmann, Michael, Shenol, Aslihan, Nissen, Tinne A. D., Petersen, Jacob E., Kouvchinov, David, Schwartz, Thue W., Frimurer, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743428/
https://www.ncbi.nlm.nih.gov/pubmed/36518697
http://dx.doi.org/10.1021/acsmedchemlett.2c00160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743428/
https://www.ncbi.nlm.nih.gov/pubmed/36518697
http://dx.doi.org/10.1021/acsmedchemlett.2c00160

Ejemplares similares